Genetic differences in GLP-1 receptor sensitivity and remaining beta cell function significantly affect individual treatment response
Despite these improvements, persistence declines sharply over longer durations, with only 14% of patients remaining on Wegovy after three years
They are often not told this upfront and, with many people stopping these drugs after only two years due to this misunderstanding, high costs, and side effects, it can lead to them possibly giving up on weight loss all together
Where MEDVi Stands Right Now - The Full Picture If you're making a decision about any MEDVi product in April 2026, here's what the verifiable evidence actually shows - the good and the concerning, side by side
Available at: Wegovy (semaglutide) Prescribing Information
Frequently Asked Questions (FAQs) What is GLP-1 RA, and how does it work